Avidity Biosciences Stock Soars On New RNA Data

Avidity Biosciences Stock Soars On New RNA Data

Source: 
BioSpace
snippet: 

Shares of Avidity Biosciences are soaring following reported early signs of clinical activity and improvement in patients with myotonic dystrophy type 1 (DM1) treated with the company’s experimental RNA-based therapeutic and lead clinical program, AOC-1001.